A new antibiotic to treat complicated intra-abdominal and urinary tract infections, and acute pyelonephritis has been launched in the UK.
Pharmaceutical company MSD has today announced the availability of ceftolozane/tazobactam (Zerbaxa) in the UK.
It is a new intravenous antibiotic for the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections in hospital settings. It is intended to offer an alternative to carbapenems.
Ceftolozane/tazobactam (1g/0.5g) is a combination product consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium.
It is administered every eight hours by an intravenous infusion lasting one hour with the treatment length normally lasting four to 14 days.
Professor David Livermore, from the University of East Anglia, said: “It’s a new antibiotic that treats Gram-negative infections, where a lot of resistance problems are now accumulating.
“Its activity against Pseudomonas is especially important,” he added.